Cidara Therapeutics, Inc.

Private investment in public equity (PIPE) transactions continue to be an important means of fundraising for publicly traded biopharmaceutical companies while the financial markets continue to recover

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from

A lot of biopharmaceutical companies have changed their strategies during the past year or two with investors less receptive to stock offerings in 2022 and 2023 than they were in the two prior years,

Cidara Therapeutics, Inc. took a series of steps 24 April that completely reinvent the company, essentially forming a new company with a new focus, Cidara CEO Jeffrey Stein said in an interview. Abou